article Open AccessTop 1% cited

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

New England Journal of Medicine · 2017 · Vol. 377(12) · pp. 1119–1131

Paul M. Ridker✉(Brigham and Women's Hospital)Giulia Renda(Harvard University)Tom Thurén(Novartis (Switzerland))Jean MacFadyen(Harvard University)William H. Chang(Novartis (Switzerland))Christie M. Ballantyne(Baylor College of Medicine)Francisco Antônio Helfenstein Fonseca(Universidade Federal de São Paulo)José Carlos Nicolau(Universidade de São Paulo)Wolfgang Köenig(Technical University of Munich)Stefan D. Anker(Charité - Universitätsmedizin Berlin)John J.P. Kastelein(Amsterdam UMC Location University of Amsterdam)Jan H. Cornel(Medisch Centrum Alkmaar)Prem Pais(Manipal Hospital)Daniel Pella(University of Pavol Jozef Šafárik)Jacques Genest(McGill University)Renata Cífková(Thomayer University Hospital)Alberto Lorenzatti(Servicio Diabetología Hospital Córdoba)Tamás Forster(University of Szeged)Zhanna Kobalava(Peoples' Friendship University of Russia)L Vida-Simiti(Iuliu Hațieganu University of Medicine and Pharmacy)Marcus Flather(University of East Anglia)Hiroaki Shimokawa(Tohoku University Hospital)Hisao Ogawa(National Cerebral and Cardiovascular Center)Mikael Dellborg(Sahlgrenska University Hospital)Paulo R.F. Rossi(Faculdade Evangélica do Paraná)Roland P.T. Troquay(VieCuri Medisch Centrum)Peter Libby(Brigham and Women's Hospital)Robert J. Glynn(Harvard University)

View via DOI Full-text PDF

Abstract

Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846 .).

Inflammasome and immune disorders Adipokines, Inflammation, and Metabolic Diseases IL-33, ST2, and ILC PathwaysCanakinumabMedicinePlaceboMyocardial infarctionHazard ratioInternal medicineConfidence intervalRandomized controlled trialClinical endpointC-reactive protein

MeSH terms

AgedAnti-Inflammatory AgentsAntibodies, MonoclonalC-Reactive ProteinCardiovascular DiseasesDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansInfectionsLipidsMaleMiddle AgedMyocardial InfarctionNeutropenia

Citations

8,809

FWCI

342.31

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Cardiac monocytes and macrophages after myocardial infarction